Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006343 · ClinicalTrials.gov registry record · Phase 3
STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
A Phase 3 study of Leukemia, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00006343: Completed Phase 3 study of Leukemia, sponsored by Novartis.
NCT00006343 is a Phase 3 study of Leukemia that has completed, run by Novartis. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006343, a Phase 3 study of Leukemia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus cytarabine for chronic myelogenous leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness of STI571 with that of interferon alfa plus cytarabine in treating patients who have newly diagnosed chronic myelogenous leukemia.
Conditions Studied
Interventions
- DRUG imatinib mesylate
- DRUG cytarabine
- BIOLOGICAL recombinant interferon alfa
Study Locations (1)
New Jersey
- Novartis Pharmaceuticals Corporation - East Hanover
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
What the finished NCT00006343 record still lists
NCT00006343 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 3 interventions - of which imatinib mesylate is the first listed.
NCT00006343 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00006343 about?
NCT00006343 is a clinical study titled "STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia". RATIONALE: Biological therapies such as interferon-alfa and STI571 may interfere with the growth of cancer cells. It is not yet known if STI571 is more effective than interferon alfa plus cytarabine for chronic myelogenous leukemia. PURPOSE: Randomized phase III trial to compare the effectiveness o...
What is the current status of trial NCT00006343?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-06. Estimated completion is 2007-03.
What conditions does trial NCT00006343 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00006343?
The interventions under investigation include: imatinib mesylate (DRUG), cytarabine (DRUG), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006343?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006343 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
RECRUITING · Phase 3
-
Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
-
Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria
COMPLETED · Phase 3
-
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
COMPLETED · Phase 3
-
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia